Research
Hormonal
Tirzepatide was recently approved for the management of obesity.
Tirzepatide can be considered as a treatment option for obesity management.
StrongSupportsmedium confidence
A novel dual agonist of Glucose-dependent insulinotropic peptide (GIP) and Glucagon-like peptide -1 (GLP- 1) receptors, Tirzepatide, was recently approved for the management of obesity.
Why this rating
The claim is based on the approval status of a drug.
Source
A New Drug for Obesity: Tirzepatide
Jaspreet Kaur Sidhu et al. · Endocrine Metabolic & Immune Disorders - Drug Targets · 2024
otherCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →